位置:首页 > 产品库 > Pam3CSK4-Biotin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pam3CSK4-Biotin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。

Pam3Cys-Ser-(Lys)4-Biotin
Pam3CSK4-Biotin 是生物素化的 Pam3CSK4。Pam3CSK4-Biotin 是 Toll 样受体 1/2 (TLR1/2) 激动剂。
生物活性

Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is aToll-like receptor1/2 (TLR1/2) agonist[1].

IC50& Target

TLR1

 

TLR2

 

体外研究
(In Vitro)

Pam3CSK4-Biotin (100 ng/mL) induces NF-κB activation from endosomal compartments[1].

分子量

1962.85

Formula

C103H192N14O17S2

Sequence Shortening

Pam3C-SKKKK

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

 ContentsAssign value
Acidic amino acidAsp (D), Glu (E), and the C-terminal -COOH.-1
Basic amino acidArg (R), Lys (K), His (H), and the N-terminal -NH2+1
Neutral amino acidGly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)0

3.  Recommended solution:

Overall charge of peptideDetails
Negative (<0)1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024